C332C Genotype of Glyoxalase 1 and its Association with Late Diabetic Complications

J. B. Groener; P. Reismann; T. Fleming; H. Kalscheuer; D. Lehnhoff; A. Hamann; P. Roser; A. Bierhaus; P. P. Nawroth; G. Rudofsky

doi:10.1055/s-0033-1345124

Experimental and Clinical Endocrinology & Diabetes, Table of Contents

Exp Clin Endocrinol Diabetes 2013; 121(07): 436-439
DOI: 10.1055/s-0033-1345124

Article

C332C Genotype of Glyoxalase 1 and its Association with Late Diabetic Complications

Glo1 Genotype and Diabetic Neuropathy

Authors

J. B. Groener

¹Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
P. Reismann

¹Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
T. Fleming

¹Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
H. Kalscheuer

¹Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
D. Lehnhoff

¹Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
A. Hamann

¹Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
P. Roser

¹Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
A. Bierhaus

^†Deceased
P. P. Nawroth

¹Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany
G. Rudofsky

¹Department of Medicine, Division of Endocrinology and Clinical Chemistry, University of Heidelberg, 69120 Heidelberg, Germany

Abstract

Aims/Introduction:

Glyoxalase 1 catalyses the detoxification of methylglyoxal, a major precursor of advanced glycation end products associated with aging, neurodegenerative diseases, and microvascular complications of diabetes. Here, we examine a possible association of a single nucleotide polymorphism of glyoxalase 1 gene (Glo1 A332C, rs4746 or rs2736654) with the prevalence of microvascular diabetic complications in patients with type 1 and type 2 diabetes.

Materials and Methods:

Genotyping was performed in 209 patients with type 1 and 524 patients with type 2 diabetes using polymerase chain reaction and subsequent cleavage by restriction endonuclease Bsa I.

Results:

Frequencies of the glyoxalase 1 genotypes were different with respect to diabetes type with a significantly higher prevalence of A332A-genotype in type 1 diabetes (35.9% vs. 27.3%; p=0.03). In type 1 diabetes, there was no correlation of any genotype with diabetic retinopathy, nephropathy or neuropathy. In contrast, type 2 diabetic patients homozygous for the C332C allele showed a significantly increased prevalence of diabetic neuropathy (p=0.03; OR=1.49 [95%-CI: 1.04; 2.11]), while no association with diabetic nephropathy or retinopathy was found. However, the significance of this association was lost after correction for multiple testing.

Conclusions:

Our data suggest a possible association of C332C-genotype of the glyoxalase 1 gene with diabetic neuropathy in type 2 diabetes, supporting the hypothesis that methylglyoxal might be an important mediator of diabetic neuropathy in type 2 diabetes.

Key words

diabetic neuropathy - detoxification - methylglyoxal - diabetes - Glo1 A332C - rs4746

Full Text

References

References
1 Phillips SA, Thornalley PJ. The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J Biochem 1993; 212: 101-105
2 Rabbani N, Thornalley PJ. Glyoxalase in diabetes, obesity and related disorders. Semin Cell Dev Biol 22: 309-317
3 Chen F, Wollmer MA, Hoerndli F et al. Role for glyoxalase I in Alzheimer’s disease. Proc Natl Acad Sci USA 2004; 101: 7687-7692
4 Thornalley PJ. Glyoxalase I – structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 2003; 31: 1343-1348
5 Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia 2009; 52: 2251-2263
6 Callaghan BC, Little AA, Feldman EL et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 6 CD007543
7 Bierhaus A, Fleming T, Stoyanov S et al. Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. Nature medicine 2012; 18: 926-33 [Epub 2012/05/15]
8 Jack MM, Ryals JM, Wright DE. Protection from diabetes-induced peripheral sensory neuropathy – a role for elevated glyoxalase I?. Exp Neurol 234: 62-69
9 Engelen L, Ferreira I, Brouwers O et al. Polymorphisms in glyoxalase 1 gene are not associated with vascular complications: the Hoorn and CoDAM studies. J Hypertens 2009; 27: 1399-1403
10 Junaid MA, Kowal D, Barua M et al. Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet A. 2004; 131: 11-17
11 Cameron AD, Olin B, Ridderstrom M et al. Crystal structure of human glyoxalase I – evidence for gene duplication and 3D domain swapping. Embo J 1997; 16: 3386-3395
12 Degaffe GH, Vander Jagt DL, Bobelu A et al. Distribution of glyoxalase I polymorphism among Zuni Indians: the Zuni Kidney Project. J Diabetes Complications 2008; 22: 267-272 [Epub 2008/04/17]
13 Ranganathan S, Ciaccio PJ, Walsh ES et al. Genomic sequence of human glyoxalase-I: analysis of promoter activity and its regulation. Gene 1999; 240: 149-155 [Epub 1999/11/24]
14 Turk Z, Cavlovic-Naglic M, Turk N. Relationship of methylglyoxal-adduct biogenesis to LDL and triglyceride levels in diabetics. Life Sci 89: 485-490
15 Jarmuzewska EA, Ghidoni A, Mangoni AA. Hypertension and sensorimotor peripheral neuropathy in type 2 diabetes. Eur Neurol 2007; 57: 91-95
16 Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861
17 Shepherd J. Dyslipidaemia in diabetic patients: time for a rethink. Diabetes Obes Metab 2007; 9: 609-616
18 Sidoti A, Antognelli C, Rinaldi C et al. Glyoxalase I A111E, paraoxonase 1 Q192R and L55M polymorphisms: susceptibility factors of multiple sclerosis?. Mult Scler 2007; 13: 446-453
19 Kalousova M, Jachymova M, Germanova A et al. Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients. Kidney Blood Press Res 33: 30-36
20 Samadi AA, Fullerton SA, Tortorelis DG et al. Glyoxalase I phenotype as a potential risk factor for prostate carcinoma. Urology 2001; 57: 183-187
21 Barua M, Jenkins EC, Chen W et al. Glyoxalase I polymorphism rs2736654 causing the Ala111Glu substitution modulates enzyme activity – implications for autism. Autism Res 4: 262-270
22 Rath J, Gowri VS, Chauhan SC et al. A glutathione-specific aldose reductase of Leishmania donovani and its potential implications for methylglyoxal detoxification pathway. Gene 2009; 429: 1-9
23 Koizumi K, Nakayama M, Zhu WJ et al. Characteristic effects of methylglyoxal and its degraded product formate on viability of human histiocytes: a possible detoxification pathway of methylglyoxal. Biochem Biophys Res Commun 407: 426-431
24 Peculis R, Konrade I, Skapare E et al. Identification of glyoxalase 1 polymorphisms associated with enzyme activity. Gene 2013; 515: 140-143 [Epub 2012/12/04]
25 Rodriguez S, Gaunt TR. Day INM. Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies. American Journal of Epidemiology 2009; Advance Access published on January 6, 2009
26 Senthilkumar K, Thirumurugan R. Impact of tobacco on glutathione s transferase gene Loci of Indian ethnics. Asian Pac J Cancer Prev 2012; 13: 5037-5042